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Introduction
Surgical resection has been considered the standard of care 
and most effective treatment for early-stage non-small cell 
lung cancer (NSCLC) (1,2). However, approximately 25% 
of early-stage NSCLC patients do not undergo surgery 
due preexisting comorbidities, older age, or refusal (1,3). 
stereotactic body radiation therapy (SBRT), also known 
as stereotactic ablative radiotherapy (SABR), has been 
proposed in order to provide a minimally invasive treatment 
that improves accuracy in delivering ultra-high radiation 
doses (4). SBRT has become accepted and adapted as an 
alternative treatment for early-stage NSCLC (5-11). 
To date, there is no consensus on the comparative 
effectiveness of SBRT versus surgery (12-14). Two randomized 
controlled trials [STARS (15) and ROSEL (16)] attempted 
to compare SBRT and surgery in the treatment of NSCLC, 
however, both trials were closed early due to low recruitment. 
A pooled analysis of these two trials suggested a better 
3-year survival with SBRT in comparison to surgery (5). 
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However, a meta-analysis comparing the effectiveness of 
SBRT and surgical resection in early-stage NSCLC found 
that 3-year survival of sublobar resection (SLR) and SBRT 
were comparable (6). Several retrospective studies have reported 
comparable outcomes between surgery and SBRT (7-10). 
Early-stage NSCLC patients receiving SBRT may differ 
from patients eligible for surgery: they tend to be older, 
have more comorbidities and lower baseline health-related 
quality of life (HRQoL) than surgical patients (9,16,17). 
The toxicity associated with SBRT and its appropriateness 
for elderly patients or less healthy patients is still a topic 
of debate (7,8,17-20). Similarly, there remains a lack of 
consensus surrounding HRQoL after surgery for early-
stage NSCLC. Several studies have found a decrease 
in post-operative HRQoL compared with pre-operative 
levels (21-23). However, others report that deficits in 
HRQoL increase in the long-term beyond baseline levels (22). 
While an abundance of literature focuses on the comparative 
effectiveness of surgery versus SBRT (7-10,13-16) 
and the impacts of each individually on HRQoL (20-27), no 
studies, to our knowledge, have examined the differences in 
quality of life (QoL) between SBRT and surgery in early-
stage NSCLC patients. The high incidence and improved 
survival for NSCLC necessitate a close examination of 
potential differential QoL between surgery and SBRT in 
early-stage NSCLC patients, as many early-stage survivors 
are able to live long lives post-treatment. Coupled with the 
unique challenges faced by lung cancer survivors including 
physical (22,28-32) and mental health difficulties (32-36), 
differential QoL between the two treatment options could 
have important implications for patient and provider 
decision-making (37). 
We hypothesize that SBRT will confer less of a negative 
impact on physical HRQoL from pre- to post-treatment as 
compared to surgery overall given the more invasive nature 
of surgery. However, our previous work has indicated that 
early-stage NSCLC SLR patients show very little HRQoL 
changes as compared to slight decrease from pre- to post-
surgery in physical HRQoL among lobectomy patients 
(21,31). Therefore, we hypothesize that surgical patients and 
SBRT patients will both demonstrate decreases in physical 
HRQoL, however, within surgical patients, lobectomy 
patients will demonstrate worse physical HRQoL decreases 
as compared to SLR patients. Further, we expect that SLR 
patients will demonstrate similar decreases in HRQoL 
to SBRT patients. Based on previous research, we do not 
expect to see significant changes in mental HRQoL in 
either the surgical or SBRT patients. 
Methods
Data source and patient population
This study used the Surveillance, Epidemiology, and End 
Results Medicare Health Outcomes Survey (SEER-MHOS) 
data set. Starting in 1998, the Center for Medicare and 
Medicaid Services has annually surveyed approximately 
1,000 to 1,200 randomly selected beneficiaries from each 
participating managed care organization in the Medicare 
Advantage program, in order to gather clinically meaningful 
data on health outcomes, including functional status, 
comorbid conditions, and HRQoL. Selected beneficiaries 
are administered a baseline survey, and a follow-up survey 
2 years later (38). This data was later linked to SEER, 
allowing for assessment of HRQoL in relation to cancer 
diagnoses and treatments. The Icahn Medical School at 
Mount Sinai Review Board for Health Sciences Research 
considered this study exempt because it relies on existing 
data without patient identifiers.
SEER-MHOS was queried from 1998 to 2014 for 
all patients with a first primary diagnosis of lung cancer, 
with surveys before and after treatment for first cancer 
diagnosis. Because some beneficiaries may have been 
selected for more than one MHOS cohort, in some cases 
the first survey was the follow-up from the earlier cohort, 
while the second survey was the baseline from a later 
cohort. For our purposes, baseline survey refers to the 
most recent survey prior to diagnosis and treatment and 
the follow-up survey refers to first survey after treatment. 
Those with a gap between surveys longer than ~2.5 years 
were excluded. Analysis was limited to patients with a 
microscopically confirmed diagnosis of a stage 0 or I lung 
cancer, who underwent only surgery or SBRT (n=184) (See 
supplementary appendix online for Figure S1 which contains 
the complete selection criteria).
Outcomes
HRQoL was measured using the 36-item Short Form 
Health Survey (SF-36) until 2006, when it was replaced 
by the Veterans RAND 12-Item Health Survey (VR-12) 
instrument. Physical Component Summary (PCS) and 
Mental Component Summary (MCS) scores were calculated 
based on individual subscale scores (including physical 
functioning, physical role limitation, pain, general health, 
emotional well-being, emotional role limitation, social 
functioning, and energy). The PCS and MCS scores have 
been normalized to the 1990 US general population (mean 
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± standard deviation, 50±10) and rescored to be equivalent 
across all cohorts/years of data collection. 
Statistical analyses
Continuous variables (PCS and MCS) are reported as means 
and standard deviations, while categorical variables (all 
covariates) are reported as percentages. Differences between 
the two treatment groups at baseline were compared using χ2 
tests (or Fisher’s exact test, where appropriate) for categorical 
variables and t-tests for continuous variables. Paired t-tests 
were used to assess changes over time in PCS and MCS 
scores from baseline to follow-up within each treatment 
group. Univariate and multivariate repeated measures 
analysis of variance (ANOVA) were performed to compare 
the change over time in the SBRT and surgery groups, by 
evaluating the interaction between treatment and time. This 
analysis was repeated to compare the sub-group of patients 
who underwent either lobectomy or SLR. Additionally, the 
analysis was repeated among those who underwent SLR 
or SBRT, since these two treatments are sometimes seen 
as alternatives for patients with poorer baseline health. 
All analyses were adjusted for age at diagnosis, gender, 
race, highest level of education attained, smoking status, 
and whether each survey was completed by proxy. When 
there was a significant difference in the presence of a 
comorbidity between the groups, the analysis was adjusted 
for the presence of that comorbidity. Comorbidities were 
assessed using the MHOS survey questions, and included 
hypertension (HTN), angina pectoris/coronary artery 
disease (CAD), congestive heart failure (CHF), myocardial 
infarction, stroke, emphysema/asthma/chronic obstructive 
pulmonary disease (COPD), and diabetes. For covariates 
with missing or unknown values, a “missing” category was 
created so as not to exclude those patients in multivariable 
analyses. Surgical and SBRT groups were also compared 
using a 1:1 propensity score matching with the Greedy 
algorithm on age at diagnosis, gender, race, education, 
baseline smoking status, completion of survey by proxy, 
and presence of emphysema/asthma/COPD, and angina 
pectoris/CAD. All statistical analyses were conducted using 
SAS software (version 9.4, SAS Institute Inc., Cary, NC). All 
P values are derived from two-tailed tests.
Results
There were 184 patients (28 with SBRT, 156 with surgery) 
who matched the selection criteria. The average time 
between surveys was 2.0 years (range, 0.8–2.3 years). The 
baseline surveys were completed, on average, 1 year before 
diagnosis and treatment (range, 0.02–2.12 years) and the 
follow-up surveys 1 year after diagnosis (range, 0.04– 
2.12 years). This did not significantly differ between the 
two groups (i.e., surgery and SBRT). Patients from both 
groups experienced a significant decline in PCS score, of 
−4.81 from the baseline to follow-up in surgery patients 
(95% CI: −6.31,−3.30; P<0.0001), while SBRT patients 
experienced a change of −5.6 (95% CI: −9.96, −1.24; 
P=0.0137). For MCS scores, surgery patients experienced 
a change of −2.96 (95% CI: −4.55, −1.37; P=0.0003), while 
SBRT patients experienced a non-significant change of 
−1.86 (95% CI: −5.4, 1.68; P=0.2902) (Figure 1). There 
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Figure 1 Change over time in PCS and MCS scores in surgery and SBRT groups. PCS, Physical Component Score; MCS, Mental 
Component Score; SBRT, stereotactic body radiation therapy.
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were significant differences in baseline PCS (P=0.0061) and 
MCS (P=0.0056) values between patients who underwent 
surgery and those who underwent SBRT, with those in 
the surgery group having higher baseline values for both. 
Patients in the SBRT group were older, with lower levels 
of education, though not significantly. Patients treated 
with SBRT were significantly more likely to have reported 
COPD, emphysema, or asthma (P<0.0001), and angina 
pectoris/CAD (P=0.0108). 
Both the univariate and multivariate analyses revealed no 
significant difference in the change over time between the 
two treatment options for either PCS or MCS score (Table 1). 
A propensity matched analysis resulted in 22 patients in 
each group. There were no significant differences in QoL 
changes between the two groups, however, the baseline 
differences in HRQoL were not significant between surgery 
and SBRT, and the change in PCS score from baseline to 
follow-up among surgical patients was no longer significant. 
(Tables S1,S2 and Figure S2 in the supplemental appendix 
online). 
Among surgery patients, there were 128 who received a 
lobectomy and 26 a SLR. Lobectomy patients experienced 
a significant change in PCS score (−4.62, 95% CI: −6.3, 
−2.93; P<0.0001) from before to after surgery, as did 
SLR patients (−5.15, 95% CI: −8.84, −1.46; P=0.0081). 
Lobectomy patients also experienced a significant change in 
MCS score (−3.11, 95% CI: −4.74, −1.48; P=0.0002), while 
the results for SLR patients were not significant (−3.12, 
95% CI: −8.01, 1.80; P=0.2035) (Figure 2). There was no 
significant difference between PCS and MCS scores at 
baseline between the two surgery types. Patients receiving 
a lobectomy were more likely to have a higher level of 
education (P=0.0294) and less likely to have their baseline 
and follow-up survey filled out by a proxy (P=0.0037 and 
P=0.0011 respectively). Lobectomy patients were also 
significantly less likely to be smokers at the time of the 
follow-up survey (P=0.0032).
Both the univariate and multivariate analyses showed no 
significant difference in the change over time between the 
two types of surgery for either PCS or MCS score (Table 1). 
Patients who underwent either SBRT (n=28) or SLR 
(n=26) were compared directly. Both groups of patients 
experienced a significant decline in PCS score from baseline 
to follow-up, while the change for MCS scores were not 
significant (Figure 3). Though not statistically significant, 
there were some differences between SLR and SBRT 
patients in baseline PCS score (P=0.0744) and MCS score 
(P=0.0700). SLR patients were significantly more likely 
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to be smokers at their baseline survey (P=0.0293), though 
that difference was not present at follow-up. SBRT patients 
were significantly more likely to have reported COPD, 
emphysema, or asthma (P=0.0039), and angina pectoris 
or CAD (P=0.0250); they were also more likely to have 
diabetes (P=0.0607).
No significant differences in the change over time, as 
measured by the treatment*time interaction were found in 
the univariate and multivariate models for PCS score or 
MCS score (Table 1). 
Discussion
Confirming our hypothesis, patients from both the 
surgical and SBRT groups demonstrated decreases in 
physical HRQoL, but, inconsistent with our hypothesis, 
the magnitude of the decline did not vary between groups. 
The only significant differences between the two groups 
was in baseline physical and mental HRQoL, with SBRT 
patients having worse QoL in both areas. This could be 
due to the fact that the SBRT patients were likely sicker 
given their significantly higher likelihood of having lung-
related comorbidities and heart disease and the fact that 
they were slightly older. The decreases in mental HRQoL, 
although significant for surgical patients, were quite modest 
and do not represent a meaningful decline in emotional 
wellbeing. This is consistent with our previous work 
involving surgical patients only, in which mental HRQoL 
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was relatively consistent across time points (24,34). It is 
possible that, despite the decline in physical HRQoL, there 
is a feeling of relief post-treatment that may counteract the 
potential negative impact of physical discomfort associated 
with treatment. It would be important to measure mental 
HRQoL at later time points though, given that recent 
qualitative research points to experiences of anxiety, 
depression and isolation that can persist long after the 
treatment has been completed (37).
Based on our previous work and the current findings 
that suggested that lobectomy conferred a greater negative 
impact on physical HRQoL as compared to SLR (34), we 
compared SBRT and SLR directly, expecting that SLR 
and SBRT patients would demonstrate a similar decline in 
physical HRQoL as compared to SBRT patients. Support 
for this hypothesis was found as there were no significant 
differences between the two groups. Physical HRQoL 
decreased in both groups although the rate of these 
decreases was not different between the two groups. Similar 
to the overall surgery group, the baseline physical and 
mental HRQoL scores were slightly lower for the SBRT 
group than for the SLR group, again likely due to increased 
prevalence of comorbidities.
Given the small sample sizes, the results of the study 
should be considered preliminary, however, the results 
suggest that surgery (regardless of type) and SBRT are 
relatively comparable in terms of the impact on physical and 
mental HRQoL and suggest that SBRT is a good alternative 
for those for whom surgery is contraindicated. The similar 
impact on HRQoL was somewhat surprising given the 
less invasive nature of SBRT, however it is likely that the 
selection bias in terms of who receives SBRT (i.e., older, 
sicker patients) may account for a greater likelihood of 
experiencing slight negative physical HRQoL impacts. Also, 
it is important to note that a certain percentage of patients 
die during surgical treatment unlike SBRT in which death 
is highly unlikely; this may have biased the sample, since 
data from the sickest, most at-risk surgical patients who die 
during surgery would not have been included in the study. 
Study results imply that treating physicians, whether 
they are surgeons or radiotherapists, need to consider the 
impact of treatment on HRQoL. It is important to discuss 
and prepare patients for these impacts so that social support 
and post-treatment care is in place ahead of surgery. Results 
from our qualitative study also suggested that coordination 
with a nurse navigator or someone in a similar type of role 
would be greatly beneficial to helping reduce the negative 
HRQoL impacts on early-stage lung cancer patients (37).
Strengths of this analysis are the access to the SEER-
MHOS data set, which allowed for the examination of 
cases from a large, representative patient data pool, and the 
possibility to directly compare QoL changes after surgery 
and radiotherapy. A limitation, however, is that after 
applying the inclusion criteria, particularly the need for 
HRQoL measurement at both a pre- and post-treatment 
time point, the sample size was ultimately quite reduced. 
An analysis of differences at baseline between those who 
completed a follow-up survey and those who did not 
revealed that the latter were significantly more likely to 
be treated with SBRT. Similar differences were observed 
with the group who was not included due to death after 
the first survey. Additionally, those who were not included 
because they did not have a valid baseline or follow-up 
were significantly older and also more likely to receive 
SBRT than those who were included. These all point to 
the possibility that the oldest and sickest patients were not 
included in the current study and that they were more likely 
to have been treated with SBRT. Perhaps the HRQoL 
scores would have appeared even worse for the SBRT group 
had these patients been included. Additionally, although 
patients completed the two surveys 1 year prior and 
1 year after diagnosis on average, the variability in the time 
frame could impact the results. It is possible that someone 
completed a HRQoL follow-up survey immediately 
following surgery, and that may result in a worse HRQoL as 
compared to someone who had completed the survey a year 
or more after treatment. Similarly, the longer time between 
diagnosis and baseline survey completion, the more likely 
the patient was in better health. These factors could create 
HRQoL changes that vary more as a function of time since 
treatment than just time between baseline and follow-
up. However, upon analysis, the time between surveys did 
not significantly vary by treatment group (i.e., surgery 
and SBRT) thereby limiting the impact that any survey 
time frame variability could have on HRQoL differences 
between treatment groups. 
As more patients are diagnosed with early-stage lung 
cancers due to increased screening, it is likely that large 
databases such as such as SEER-MHOS will have more 
cases with data from multiple time points. Future research 
should leverage such databases, but also prospective studies 
of early-stage lung cancer treatment impacts are needed 
to truly understand and differentiate effects on HRQoL. 
Further, measurement should extend beyond QoL to also 
include more specific measures of physical health such as 
pain and sleep and more specific measures of mental health 
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such as anxiety and depression. It is possible that using more 
refined and specific tools will elucidate greater treatment 
differences that will ultimately inform treatment decision-
making for early-stage lung cancer patients.
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Supplementary
SEER-MHOS Lung Cancer Records
n=16,771
Survey records before and after treatment
n=618
Patients with stage 0 or I
n=203
Sample size:
Patients with only surgery or SBRT n=184
Excluded:
Cancer not microscopically confirmed (n=35);
Not stage 0 or I at diagnosis (n=380)
Excluded: 
Underwent multiple treatments or no 
treatment (n=19)
Excluded:
Lung cancer not first primary (n=3,919);
Missing record before treatment (n=3,190);
Missing record after treatment (n=8,962);
Gap >2.5 years in survey records (n=82)
Figure S1 Selection criteria. SEER-MHOS, Surveillance, Epidemiology, and End Results Medicare Health Outcomes Survey; SBRT, 
stereotactic body radiation therapy. 
Figure S2 Change over time in PCS and MCS scores in surgery and SBRT groups, propensity matched cohort (n=44). PCS, Physical 
Component Score; MCS, Mental Component Score; SBRT, stereotactic body radiation therapy; Srg, surgery.
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Table S1 Comparison of surgical and SBRT groups before and after propensity matching on demographics
Variable
P value 
Before propensity matching After propensity matching*
Age at diagnosis 0.2080 0.8840
Gender 0.9217 0.7055
Race 0.9739 1.0000
Education 0.1590 0.4795
Smoking status 0.1086 0.3173
Survey completed by proxy 0.7357 0.5271
COPD/emphysema/asthma <0.0001 0.3173
Angina pectoris/CAD 0.0108 0.4797
Before propensity matching, n=184 (156 surgery, 28 SBRT); After propensity matching, n=44 (22 surgery, 22 SBRT). *, matched on age 
at diagnosis, gender, race, education, smoking status, whether the baseline survey was completed by proxy, and presence of COPD/
emphysema/asthma, and angina pectoris/CAD. COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; PCS, 
Physical Component Summary; MCS, Mental Component Summary; SBRT, stereotactic body radiation therapy.
Table S2 Comparison of surgical and SBRT groups before and after propensity matching on baseline QoL
Quality of 
life
Before propensity matching, mean (SD) After propensity matching*, mean (SD)
Surgery SBRT P value Surgery SBRT P value
PCS 39.6 (11.8) 32.9 (10.2) 0.0061 32.5 (13.9) 33.6 (10.8) 0.7628
MCS 52.3 (10.0) 43.8 (14.4) 0.0056 51.2 (11.0) 45.1 (14.9) 0.1553
Before propensity matching, n=184 (156 surgery, 28 SBRT); After propensity matching, n=44 (22 surgery, 22 SBRT). *, matched on age 
at diagnosis, gender, race, education, smoking status, whether the baseline survey was completed by proxy, and presence of COPD/
emphysema/asthma, and angina pectoris/CAD. COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; PCS, 
Physical Component Summary; MCS, Mental Component Summary; SBRT, stereotactic body radiation therapy; SD, standard deviation.
